You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股受捧 新藥上市獲批信達生物(01801.HK)急漲15%
信達生物(01801.HK)澄清聲明指,旗下用於一線治療食管鱗癌新適應症的創新藥物PD-1抑制劑達伯舒上市申請已獲批準,而非原公告中受理上市申請。該股三連升,今天升破百天線(27.9元),午後高見31.3元,現報31.1元,急漲15%,成交增1,688萬股。 其餘醫藥股也普遍造好,騰盛博藥(02137.HK)三連升,今天最高見9.09元,現報8.9元,漲8.8%。康希諾(06185.HK)午後高見81.8元,現報81.15元,升6.2%。 歌禮制藥(01672.HK)、威高股份(01066.HK)、君實生物(01877.HK)、金斯瑞生物(01548.HK)、開拓藥業(09939.HK)、三葉草生物(02197.HK)及藍籌藥明生物(02269.HK)升近4%-6%,後者股價三連漲,午後高見72元,現報71.65元,續升5.8%。 藥明康德(02359.HK)、上海醫藥(02607.HK)、國藥(01099.HK)、中生製藥(01177.HK)、石藥(01093.HK)、復星醫藥(02196.HK)及四環醫藥(00460.HK)升逾1%-3%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account